6^th International Conference on Rare Diseases & Orphan Drug June 17-18, 2019 MENA Plaza Hotel Albarsha | Dubai, UAE

She has Doctor Degree in Microbiology and Immunology. She has established the Quality Control Program of vaccines and the Brazilian Biosafety Program at the Ministry of Health in Brazil, where she has worked for 38 years. She has mentored quality control and biosafety trainings as an international consultant. She has founded the Brazilian Biosafety Association and the International Federation of Biosafety Associations. She was Chairperson of the Brazilian Biosafety Committee and has represented Brazil in several international agreements. She was adviser to many countries on Biosafety of Biotechnology procedures and she was awarded by the International Federation of Biosafety Association as Biosafety Hero in 2015.

Biotechnology

Bryan Gutierrez has completed his Bachelor degree in Pharmacy at the University of Santo Tomas. He is currently a pharmacist at Al Zahra Private Hospital Dubai. He specializes in the knowledge, handling, and extemporaneous compounding of chemotherapy medications and regimens. He designed the Pharmacology in Critical Care Course which include basic and clinical pharmacology in the critical care. Clinical Pharmacist-In-Charge, First Successful All-Filipino Pediatric Liver Transplant in the Philippines.

chemotherapy medications and regimens, Clinical pharmacology

Lecturer and medical oncology specialist in Clinical Oncology department, Faculty of medicine, Suez Canal University Hospital, Ismailia, Egypt. Author at Medical Fraternity – an online super-speciality physician case based learning platform. Ph.D. degree in Clinical and Experimental Oncology and Immunology, department of Surgery, Oncology and Gastroenterology, Padua University and Veneto Oncology Institute, Padua, Italy. I was involved in basic research, clinical activities and following clinical trials. Courses studied are the following: Oncology, Cancer virology, Oncohematology, Tumour immunology, Genetics and Bioinformatic analyses, Methods of imaging in medicine and biology, Biostatistics, Bioethics, Bibliometrics, Communicating science effectively.

Oncology, Cancer virology, Genetics, Methods of imaging in medicine and biology, Tumour immunology

Consultant thoracic and breast oncological surgery through the period 1991-2018 in Latakia national hospital, ministry of health. I was named the chief of residency training program in Latakia directorate of health in 2010. I was appointed chief of surgical departments, international member of American society of Breast surgeon, lecturer and founder member of the Syrian foundation for breast cancer support in Latakia. Private experience in breast cancer, screening, detection and surgery.

Thoracic, Breast oncological surgery

Jeff Leider, of Elmwood Park, New Jersey, has been on the forefront of Rare Disease Awareness for a little over five years now. His passion for advocacy began when his sons were diagnosed with MPS II/Hunters Syndrome. Since that heart wrenching day of diagnosis, he has worked tirelessly not only for his children but all children with Rare Diseases. Jeff is the President and Founder of the Let Them Be Little X2 Foundation. Mr. Leider has been on the forefront of bringing legislation to our governmental agencies. With Mr. Leider’s assistance and leadership a new law, The Let Them Be Little Act, providing testing of MPS I & MPS II in newborns, was recently signed into law by Governor Chris Christie. This is only the second state in the Union to implement this law. Mr. Leider has also been an integral part, with the support and guidance of Congressman Bill Pascrell (D-NJ9), in persuading the FDA and Shire Pharmaceuticals to open a clinical trial, allowing nine children diagnosed with Hunters Syndrome a chance to receive experimental drug to halt disease progression. Locally Mr. Leider is a Board Member for the Elmwood Park Youth Football Bombers and Officer of the Elmwood Park Little League. In November 2014, Mr. Leider was the award recipient of The Abby at the Rare Voice Awards in Washington, DC for advocacy at the State Level.

Rare Disease Awareness

Dr Shrutti Dhar currently working as Country Brand Lead for Rare Diseases India. In this role she is responsible for all the Pfizer rare diseases products and work actively to launch them in India and provide access to those patients who need it. Her areas of focus are Hemophilia, Sickle cell disorders and Gauchers Diseases for which Pfizer has an exciting pipeline of new products. Previously she was responsible for Medical affairs for Rare Diseases India. As a Medical Lead she was actively working with key decision makers in Government and private sector to Increase awareness, improve diagnosis and provide access to rare diseases therapies.

Hemophilia, Sickle cell disorders and Gaucher's Diseases

I am Dr.Mojtaba Mafi M.D., Medical Doctor/ Physician, Graduate of Tehran university, School of Medicine with honor. I passed post graduate courses on Nutrition, Gastroenterology and hepatology, Obesity treatment and diabetes approved by Medical sciences university successfully. I am associate of Iran Hepatitis Network and Gastroenterology and Hepatology research center, Middle East Liver Diseases Center (MELD). I studied on fatty liver and related metabolic disorders among Iranian families from 2015 and currently publishing the results of our study and research about fatty liver and hyperlipidemia, diabetes and nutrition as study director and clinician associate member of Hepatitis Network. I am reviewer of Hepatitis Monthly Journal and journal of Clinical and Translational Hepatology. I passed successfully more than 10 courses with certificates in Iranian association of gastroenterology and hepatology. One of my works on diabetes and fatty liver as a scientific article has been accepted in 4th International Conference on Diabetes and Its Treatments at Dubai 2018 for oral presentation and publication. I am organizing committee member and speaker of International Conference of Nutrition and Diet Imbalance, Indonesia, 2018. My article on fatty liver and metabolism has been accepted in International Conference on Gastroenterology and hepatology, Thailand 2018, for oral and poster presentation. I am verified reviewer and certified mentor of Publons academy in the field of Clinical Medicine and Hepatology. I am invited participant for International Conference of Translational Medicine, Hawaii, from editor in chief of American Journal of Translational Medicine. I am invited speaker of International Conference on Obesity and Chronic diseases, 2018 in Dubai.

Hepatology, Liver Diseases, Gastroenterology

Dr. Neusa O.V.T Lopes, MD, Pulmonologist, is a graduate of Christian University Medical School, Jakarta Indonesia as a medical doctor. 2015 she finished her specialization in Respiratory medicine at the University of Indonesia. Dr. Neusa has been practicing since 2004, the last 10 years at National Hospital Guido in Dili, Timor-Leste, one of the Timor’s top referral hospitals, where in her practice, she specializes in the care of critically ill, respiratory diseases. She is board certified in pulmonary medicine and respiratory disease by Indonesia medical board. She also a President of the Multi Drug Resistant Tuberculosis Program of Ministry of Health, East Timor. Certified by the FDA for Clinical Trials and a member of the Conduct Clinical Trial program, based in California, USA. Dr. Neusa is a member of Indonesia pulmonologist association and Timor-Leste medical association. Her first research, entitled, “Cohort Review Six months of MDR TB in Timor-Leste and Persahabatan Hospital” was published in Journal of Respiratory in Indonesia. In addition, her second research study with the title “Lung Cancer in Young Males”, was published in the Respiratory Journal in Sydney, Australia, and in ECRON, London. Her research interests are related to lung cancer occurring at young ages, drug resistant tuberculosis and advance tuberculosis. She strongly believes that understanding the basic physiology, pathophysiology, immunology and genetic inherent also genetic mutation of the disease will ultimately lead to better holistic management or even a cure for cancer and drugs resistant.

Lung cancer,Drug-resistant tuberculosis, Immunology, Pathophysiology

Dr. Ali is a Clinical and Molecular geneticist certified by the American Board of Medical Genetics and Genomics (ABMGG), currently serving as medical director in global clinical development at Ultragenyx pharmaceutical in California, USA. Dr. Ali’s experience includes clinical genetics practice [full-time/USA previously and telemedicine/MENA currently], leadership and directorship roles at a CLIA-CAP certified DNA diagnostic laboratory/USA [previously], and translational research experience at the National Institutes of Health (NIH)/USA [previously]. Dr. Ali also sits on the gene editing task force/gene therapy committee at Alliance for Regenerative Medicine (ARM) and pediatric expert work group at the International Conference on Harmonisation (ICH).

Gene therapy, Pediatric expert

Samer Ellahham has served as Chief Quality Officer for SKMC since 2009. In his role, Dr. Ellahham has led the development of a quality and safety program that has been highly successful and visible and has been recognized internationally by a number of awards. As Chief Quality Officer and Global Healthcare Leader, he has a focus on ensuring that that implementation of this best practices leads to breakthrough improvements in clinical quality and patient safety. He Ellahham is a recognized leader in quality, safety, and the use of robust performance improvement in improving healthcare delivery. He serves on a number of US and international committees and advisory bodies. Samer Ellahham is Certified Professional in Healthcare Quality (CPHQ) by The National Association for Healthcare Quality (NAHQ). He is certified in Medical Quality (CMQ) by The American Board of Medical Quality (ABMQ). He is the recipient of the Quality Leadership Award from the World Quality Congress and Awards and the Business Leadership Excellence Award from World Leadership Congress in 2015. He is one the nominees for Safe Care magazine Person of the Year in the United States

heart failure, genetics, cardiac imaging, sports and nutrition, innovation, safety, outcomes research, risk management, safe surgery.

Dr. Mohamad Miqdady is American Board certified in Pediatric Gastroenterology, Hepatology and Nutrition. He is the Division Chief, Ped. GI, Hepatology & Nutrition Division at Sheikh Khalifa Medical City in UAE. Program Director, Pediatric Gastroenterology Fellowship Training program, SKMC, Abu Dhabi, UAE. Also an Adjunct Staff at Cleveland Clinic, Ohio USA. Expert member of the FISPGHAN Council (Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition); Malnutrition/Obesity Expert team. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children’s Hospital in Houston, TX, USA. He held the position of Assistant Professor at Jordan University of Science and Technology in Jordan for six years prior joining SKMC. Main research interests include nutritional disorders, feeding difficulties, picky eating, obesity, procedural sedation, allergic GI disorders and celiac disease. He has 20 publications in peer reviewed journals. On the Editorial Board of few journals including Gastroenterology & Hepatology.

Pediatric Gastroenterology, Hepatology and Nutrition

Yavuz is the chairman of Istanbul Consulting Group. ICG(Istanbul Consulting Group) was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project.Yavuz is currently the Co-Founder of BioCube İstanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Sumitomo Group/ Expel İlaç Archem Diagnostices Endmed and Diagen. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey. Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories. Yavuz earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis. Yavuz currently resides with his wife Dr. Kamile Sılay and their two daughters and one son in Ankara,Turkey.

Pharmaceutical, Biotech

Dr Timothy Low is currently the Head of Medical Affairs Asia Pacific at Shire, a position he assumed on October 2, 2017, based in its regional headquarters in Singapore. He was awarded 2018 Rare Disease Champion Provider of the Year in Asia Pacific. Concurrently in 2018, he was also conferred the Icons of Healthcare – Leading Healthcare Management Professional of the year. Prior to joining Shire, Dr Low served for two years as Chief Executive Officer (CEO) of Farrer Park Hospital, a private acute tertiary institution sited within Singapore’s first fully integrated healthcare and hospitality complex. It was awarded “Best New Hospital in Asia Pacific” and “Smart Hospital of the Year in Asia Pacific” in 2016/2017 respectively. He currently serves as a member of the hospital’s Board of Directors. With 30 years tenure in both public and private practice, Dr Low brings to his role his operational and medical knowledge, along with his extensive strategic experience leading teams and bringing specialty care to patients. He formerly held the positions of CEO of Gleneagles Hospital from 2000 to 2006 and as Medical Affairs senior executive across pharmaceutical and medical device industries at Covidien, Schering Plough, Covance and GlaxoWellcome, spanning more than 17 years. Dr Low joins the prestigious ranks of Stanford Who’s Who for his contributions toward the healthcare community. He was also awarded the “50 Most Talented Healthcare Leaders of Asia” award as well as “Best CEO of the Year” at the Asia Healthcare Excellence Award conferred by CMO Asia in 2016 and 2017 respectively. Dr Low received his Bachelor of Medicine and Bachelor of Surgery from the National University of Singapore (NUS) and started his professional career in Public Service at various local hospitals and as a General Practitioner at Raffles Medical Center. He also holds various graduate degrees awarded by the NUS Graduate School of Business, Stanford University Executive Programme and the Singapore Management University Asia Pacific Hospital Management Programme.

Rare Disease

Dr Stef Stienstra works internationally for several medical and biotech companies as scientific advisory board member and is also an active reserve-officer of the Royal Dutch Navy in his rank as Commander (OF4). For the Dutch Armed Forces he is CBRNe specialist with focus on (micro)biological and chemical threats and medical- and environmental functional specialist within the 1st CMI (Civil Military Interaction) Battalion of the Dutch Armed Forces. For Expertise France he is now managing an EU CBRN CoE public health project in West Africa. He is visiting professor for the University of Rome Tor Vergata in Italy for the CBRN Masters Course and lecturer for the NATO School in Oberammergau in Germany and the Joint NATO CBRN-Defense Center of Excellence in Vyskov in the Czech Republic. In his civilian position he is at this moment developing with MT-Derm in Berlin (Germany) a novel interdermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative blood separation unit, which is also suitable to produce convalescent plasma for Ebola Virus Disease therapy. He has finished both his studies in Medicine and in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-haematology, infectous diseaases, biodefense and transfusion medicine. His natural business acumen and negotiation competence helps to initiate new successful businesses, often generated from unexpected combinations of technologies.

cell biology, immuno-haematology, infectous diseaases, biodefense and transfusion medicine

Dr Samrat Shah has completed his MD(Internal Medicine) from KLE University-Karnataka. He is gold medalist in Internal Medicine. He has done Fellowship in Diabetology from Dr.Mohans Acadamy (IDF approved). He is presently working as Consultant Physician At Mediheal Group Of Hospitals. He has 6 International publications and several National and Regional publications.

Internal Medicine, Diabetology